https://www.nature.com/articles/s41467-025-59279-z...

Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial https://www.nature.com/articles/s41467-025-59279-z